Premium
Development of a Malaria T‐Cell Vaccine for Blood Stage Immunity
Author(s) -
QUAKYI I. A.,
TAYLOR D. W.,
JOHNSON A. H.,
ALLOTEY J. B.,
BERZOFSKY J. A.,
MILLER L. H.,
GOOD M. F.
Publication year - 1992
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1992.tb01611.x
Subject(s) - epitope , biology , malaria , plasmodium falciparum , immunity , virology , immunology , immune system , population , malaria vaccine , t cell , antigen , major histocompatibility complex , medicine , environmental health
We have defined a strategy for the development of a T‐cell vaccine for blood stage immunity, taking into consideration the central role of T cells and MHC restriction in malaria immune responses. We have used the AMPHI computer algorithm lo identify putative T‐cell epitopes from conserved regions of 11 Plasmodium falciparum asexual stage proteins. Ten of the eleven proteins arc currently candidates for vaccine development. Using this algorithm we selected 22 putative T‐cell epitope peptides und 8 control peptides. These peptides were used to test the T‐cell responses of three defined populations of Caucasians who have (1) recovered from P. falciparum malaria. (2) been exposed, but never clinically infected, (3) never been exposed or infected. Preliminary analysis of our data shows population differences in T‐tell responses to putative T‐cell epitope peptides. Ultimately, these studies will help to identify those T epitopes that can be incorporated into a T‐cell vaccine for protective immunity.